Hematopoietic Stem Cell Transplantation in Thalassemia.
Cord blood transplantation
Haploidentical transplantation
Hematopoietic stem cell transplantation
Hemoglobinopathies
Sibling donor transplantation
Thalassemia
Unrelated donor transplantation
Journal
Hematology/oncology clinics of North America
ISSN: 1558-1977
Titre abrégé: Hematol Oncol Clin North Am
Pays: United States
ID NLM: 8709473
Informations de publication
Date de publication:
04 2023
04 2023
Historique:
entrez:
12
3
2023
pubmed:
13
3
2023
medline:
15
3
2023
Statut:
ppublish
Résumé
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only consolidated, potentially curative treatment for patients with transfusion-dependent thalassemia major. In the past few decades, several new approaches have reduced the toxicity of conditioning regimens and decreased the incidence of graft-versus-host disease, improving patients' outcomes and quality of life. In addition, the progressive availability of alternative stem cell sources from unrelated or haploidentical donors or umbilical cord blood has made HSCT a feasible option for an increasing number of subjects lacking an human leukocyte antigen (HLA)-identical sibling. This review provides an overview of allogeneic hematopoietic stem cell transplantation in thalassemia, reassesses current clinical results, and discusses future perspectives.
Identifiants
pubmed: 36907612
pii: S0889-8588(22)00150-2
doi: 10.1016/j.hoc.2022.12.009
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
413-432Informations de copyright
Copyright © 2022 Elsevier Inc. All rights reserved.